Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699031 | 1.00 | MEN1 (0.34) | MEN1KMT2APDE10AMAP4K1SPHK2 | |
| SCHEMBL20733270 | 0.84 | PDE10A (0.33) | MEN1KMT2APDE10AMAP4K1 | |
| SCHEMBL19699033 | 0.82 | MAP4K4 (0.42) | MEN1KMT2A | |
| SCHEMBL19699032 | 0.80 | MAP4K4 (0.41) | MEN1KMT2APDE10A | |
| SCHEMBL19699030 | 0.74 | MEN1 (0.45) | MEN1KMT2A | |
| SCHEMBL20733299 | 0.68 | EGLN2 (0.39) | — | |
| SCHEMBL16754611 | 0.68 | MAP4K4 (0.32) | MEN1KMT2A | |
| SCHEMBL17778533 | 0.68 | MAP4K4 (0.32) | MEN1KMT2A | |
| SCHEMBL16754694 | 0.68 | MAP4K4 (0.32) | MEN1KMT2A | |
| SCHEMBL16754610 | 0.68 | MAP4K4 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MEN1 3676/4885KMT2A 1438/4885PDE10A 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.